Humana's Bold Goal progress report aims to improve population health by addressing health barriers, increasing access to healthcare, encouraging healthy behaviors, and promoting the prevention and management of chronic conditions prevention and management.
De-escalated maintenance or “drug holidays”: What’s best for patients with metastatic colorectal cancer?
Most patients hear the word “carcinoma” or “cancer” and believe they may die if they do not seek treatment. But ASCO researchers say that may be a problematic mentality.
Biosimilars will have a significant impact on cancer treatment, with the potential to drive cost savings, but will patients and providers be accepting?
FDA is warning consumers about the risk of serious bleeding when using over-the-counter aspirin-containing antacid products to treat heartburn. The agency also issued a separate warning about loperamide (Imodium, Johnson & Johnson), saying that abuse or misuse of the product can cause serious heart problems that can lead to death.
Health plans and healthcare organizations are increasingly facing threats from cyber criminals. Here's how to better protect your organization.
Targeted treatments of HER2-positive breast cancers have dramatically prolonged many patients’ lives. But treatment outcomes in clinical trial settings don’t always translate into comparable real-world clinical value.
Patient-reported outcomes are playing a growing role in cancer research and are poised to become an important part of regulatory review in drug development-and even routine clinical cancer care.
The first and only fixed-dose combination of a beta blocker beta blocker (BB) and angiotensin II receptor blocker (ARB) for hypertension will be available in the US in the second half of the year. FDA approved nebivolol and valsartan (Byvalson, Allergan) 5 mg/80 mg tablets in early June.
A look at how burnout affects providers, their patients, and the centers that employ them.
Expanded access or “compassionate use” programs allow patients to use investigational treatments, medical devices, or tests, before they have received FDA approval.
ASCO 2016 presenters share how combination therapies and biomarkers can better identify which tumors are likely to succumb to particular immunotherapies
FDA recently approved daclizumab (Zinbryta, Biogen and AbbVie), a once-monthly, self-administered, subcutaneous treatment for relapsing forms of multiple sclerosis (RMS).
The ACA has done a lot of good, but key opinion leaders believe there’s still room for improvement.
Determining what to measure, and how best to measure it, can be surprisingly complex-and appropriate metrics can vary between cancer types and patient populations.
The hurdle for managed care organizations is not identifying individuals who may benefit from support, rather, it’s finding a way to tailor efforts to engage members in the solutions being offered.
The global oncology market was worth $107 billion in 2015, and global annual cancer drug costs surged by 11.5% from 2011 to 2015, according to a new report.
There’s no silver bullet for migraine treatments, but treatments are getting more precise as we learn more about the cause of migraines.
The CDC says that one out of three older adults falls each year, making falls the leading cause of injuries for adults 65 and older. Here’s how some hospitals and programs are addressing the problem.
Report offers some clues regarding healthcare spending disparities
FDA recently approved the first 4-strain, cell culture-derived, inactivated seasonal flu vaccine available in the United States. Flucelvax Quadrivalent influenza vaccine (Seqirus) helps protect against the 2 influenza A viruses and two B viruses recommended by the World Health Organization (WHO) and the FDA for the current influenza season.
In a major new entry in the diabetes market, FDA just approved linagliptin and metformin hydrochloride extended-release tablets (Jentadueto XR, Boehringer Ingelheim and Eli Lilly and Company) to treat type 2 diabetes.
A discussion with Thomas H. Lee, MD, chief medical officer, Press Ganey
Despite their proliferation, at-risk pharma contracts are still little more than value-based window dressing. Here are four critical components of contracts that can actually move the value meter in the right direction.
Industry experts are using their proprietary data/analysis to help structure contracts between pharmaceutical companies and plans.
Novo Nordisk’s new diabetes drug production facility in Clayton, N.C., will ensure production capacity for these drugs in the United States for the decade ahead.
A systemic review highlights studies that improved medication adherence and patient outcomes using strategies that could be effective if employed in real-world healthcare settings.
Drug shortages take a toll, especially on emergency department patients.
Preventing drug shortages requires a “swat team” mentality by all, including FDA, manufacturers, group purchasing organizations (GPOs), and health systems. Here’s what healthcare providers should do about the issue.
